TerrAscend Appoints Matthew J. Johnson as President, TerrAscend Corp. and TerrAscend USA

–Senior Healthcare Executive with Extensive Integration and Transaction Experience–

TORONTO, Nov. 29, 2018 /PRNewswire/ – TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or the “Company”), today announced the appointment of Matthew J. Johnson as President, TerrAscend Corporation and TerrAscend USA, effective immediately. In this senior executive role, Mr. Johnson will be responsible for leading TerrAscend’s newly-formed U.S. operations. Michael Nashat will continue in his role as the Company’s Chief Executive Officer.

Mr. Johnson, a seasoned healthcare industry executive with over 25 years of experience, has held multiple senior-level positions with several large medical device and pharmaceutical companies including AbbVie, a company with $28 billion in 2017 revenue, which was spun-out of Abbott Laboratories in 2013. Most recently, he led the AbbVie Transition Office and was responsible for managing enterprise-wide transformation efforts, including merger integration. Prior to this, he headed Global Alliance Management within Abbott’s pharmaceuticals division where he drove collaboration strategy planning, alignment and communication among project teams for all of Abbott’s partnered pipeline products. Mr. Johnson’s Abbott expertise also includes merger, acquisition and licensing for Abbott’s global pharmaceuticals business, where he led new market initiatives and business development opportunities.

Additional senior level experience includes P&L management, operations in mature and emerging international markets, business development, marketing and finance, attained while serving in leadership roles with Brunswick Corporation and Baxter Healthcare Corporation.

Mr. Johnson earned an MBA degree with honors from the Kellogg Graduate School of Management, Northwestern University, and a BA degree in Economics from the University of Vermont.

Matt is a significant addition to the TerrAscend team as we execute and build a leading international cannabis company. His extensive experience successfully executing multi-billion dollar M&A transactions and leading their complex integrations is crucial as we expand into the U.S. cannabis market.

Jason Wild, Chairman of TerrAscend

Michael Nashat, Chief Executive Officer stated, “I am thrilled to have Matt, a senior-level pharmaceutical executive, join TerrAscend’s leadership team. We look forward to working with him as we implement our significant growth plans.”

About TerrAscend Corp.

TerrAscend Corp. is a biopharmaceutical and wellness company that is committed to quality products, brands and services for the global cannabinoid market. The Company provides support to patients and consumers through its wholly-owned subsidiaries, TerrAscend Canada Inc., a licensed producer of cannabis pursuant to the Cannabis Regulations under the Cannabis Act (Canada) that provides medical cannabis to patients through its online medical marketplace Solace Health, and Solace Health Network Inc., a clinical support program and education platform led by healthcare professionals. The Company participates in the legal adult-use market in Canada through direct and indirect supply agreements in several provinces and has stated its intention to expand into the US market in states where cannabis has been legalized for therapeutic or adult-use. The Company also has an interest in Ascendant Labs, a cannabis biotechnology and licensing company committed to the continuous improvement of the cannabis plant, which is a strategic joint venture with leading researchers Cistron Corp.

Original Press Release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter